GlobeNewsWire
09 Mar 2026, 12:35 UTC · 29w ago
Verdict
Headline takes no side. We score ICU +0.20 across four claims — slightly bullish.
+0.20slightly bullish
More positive than 57% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
SeaStar Medical is conducting a pivotal trial of its SCD therapy for adult patients with AKI, a condition affecting over 200,000 U.S. adults annually.
So whatPositive trial results in a large addressable market would be a primary driver for the company's valuation and growth.
More positive than 93% of claims this week
The FDA has granted Breakthrough Device Designation to SeaStar's SCD therapy for four therapeutic indications.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 79% of claims this week
SeaStar Medical's first commercial product, QUELIMMUNE, is the only FDA-approved product for life-threatening AKI in critically ill pediatric patients.
More positive than 67% of claims this week
CEO Eric Schlorff will participate in a fireside chat and 1x1 meetings at the Life Sciences Investor Forum on March 11, 2026.
So whatInvestor presentations are routine and typically have low immediate price impact unless unexpected guidance is provided.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 57% of ticker scores this week
The company is presenting at an investor forum and highlighting its FDA-approved product and breakthrough designations.
More positive than 51% of ticker scores this week
The company is scheduled to present at a life sciences investor forum.
Near neutral — 92% of ticker scores this week are stronger
Mentioned in a brief recommended reading snippet without any specific news or sentiment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
+31.3%
Price agrees with the score
$3.31 vs $2.52 close before publication (Mar 6) · not market-adjusted
ICU chart →
